Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 75c, offers outlook

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q1 EPS of ($0.85), $0.75 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $0 versus the consensus estimate of $55.89 million.

2026 Financial Guidance

Based on our current operating plans, including the net effects of the Astellas global collaboration, the Astellas equity investment and the completion of the recent equity financing, the Company expects its cash, cash equivalents and investments to fund operations into the second half of 2028.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Creatd files Form S-1 and reports Q1 2026 financial results
• TEOCO selects Strategy One platform for telecom invoice analytics